uniQure N.V. Ordinary Shares vs Sociedad Quimica y Minera S.A. Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Sociedad Quimica y Minera S.A. Common Stock trades at $61.57 (market cap $17.95B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is far larger — about 12.1× uniQure N.V. Ordinary Shares's market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.86% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Sociedad Quimica y Minera S.A. Common Stock for 6 Days on average.
| QURE | SQM | |
|---|---|---|
Market Cap | $1.48B | $17.95B |
Volume | 2,488,780 | 910,047 |
Sector | Health | Basic Materials |
52-Week High | $70.59 | $95.31 |
52-Week Low | $9.03 | $42.39 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $728.62M | $18.81B |
Dividend Yield | — | 3.86% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SQM trades at $62.83, up 0.58% today, but technical indicators signal a bearish trend with strong selling pressure. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.31 vs. $2.03 expected, while Q1 and Q4 2025 missed expectations. Valuation metrics appear attractive with P/E of 12.93 and EV/EBITDA of 7.09, supported by strong profitability margins including 42.17% gross margin and 23.78% ROE.
Despite near-term technical weakness, SQM's fundamentals remain solid with projected revenue growth to $6.7B in 2026 and net profit margin expansion to 20.62%. The consensus price target of $92.50 suggests 47% upside potential, though lithium price volatility and recent earnings misses present execution risks. Analyst sentiment is mixed with 31% Buy ratings versus 19% Sell recommendations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.
Read more on SQM →